Implanet SA (IM11.BE)
| Previous close | 0.0722 |
| Open | 0.0680 |
| Bid | 0.0792 x N/A |
| Ask | 0.1130 x N/A |
| Day's range | 0.0680 - 0.0680 |
| 52-week range | 0.0201 - 0.1300 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireIMPLANET Receives FDA Clearance for Its New Hybrid Fixation System Jazz Spinal SystemTM
BORDEAUX, France & BOSTON, May 13, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, today announced the Food and Drug Administration (FDA) 510(k) clearance of its new hybrid fixation system Jazz Spinal SystemTM.
Business WireMinutes of IMPLANET’s Ordinary General Meeting held on April 25, 2024
BORDEAUX, France & BOSTON, April 25, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, informs its shareholders that its Ordinary General Meeting was held on Thursday April 25, 2024, at 2:00 pm CEST at the Company's registered office, in Martillac.
Business WireIMPLANET Reports its 2024 First-Quarter Revenue
BORDEAUX, France & BOSTON, April 09, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, today announces its revenue for the first quarter of 2024.
